Literature DB >> 21308499

The HIV-Infected Adolescent.

Allison C Ross1, Andres Camacho-Gonzalez, Sheryl Henderson, Francisca Abanyie, Rana Chakraborty.   

Abstract

HIV-infected adolescents represent a unique, yet diverse, population requiring specialized medical and psychosocial HIV care. Perinatally infected and behaviorally infected adolescents often have differing therapeutic needs, but may share common difficulties, including medication nonadherence, high-risk sexual behavior, psychosocial stressors, and concomitant psychiatric disorders. Addressing these needs within a culturally sensitive framework and in the context of a population-specific approach to treatment is paramount to optimizing care. Harm reduction for this group to maximize their health and limit HIV transmission to others is also critical with respect to the rising incidence of newly diagnosed HIV-positive adolescents. Implementing a formal, multidisciplinary program that involves individual youths and their families for improved transition to adult HIV care will afford such adolescents a better chance for a healthy adulthood.

Entities:  

Year:  2010        PMID: 21308499     DOI: 10.1007/s11908-009-0077-4

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.663


  46 in total

1.  A consensus statement on health care transitions for young adults with special health care needs.

Authors: 
Journal:  Pediatrics       Date:  2002-12       Impact factor: 7.124

2.  Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.

Authors:  Patrick Dorr; Mike Westby; Susan Dobbs; Paul Griffin; Becky Irvine; Malcolm Macartney; Julie Mori; Graham Rickett; Caroline Smith-Burchnell; Carolyn Napier; Rob Webster; Duncan Armour; David Price; Blanda Stammen; Anthony Wood; Manos Perros
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

3.  Health literacy and antiretroviral adherence among HIV-infected adolescents.

Authors:  Debra A Murphy; Phebe Lam; Sylvie Naar-King; D Robert Harris; Jeffrey T Parsons; Larry R Muenz
Journal:  Patient Educ Couns       Date:  2009-08-08

4.  Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1.

Authors:  Christine Katlama; Roberto Esposito; Jose M Gatell; Jean-Christophe Goffard; Beatriz Grinsztejn; Anton Pozniak; Jurgen Rockstroh; Albrecht Stoehr; Norbert Vetter; Patrick Yeni; Wim Parys; Tony Vangeneugden
Journal:  AIDS       Date:  2007-02-19       Impact factor: 4.177

5.  Infrequent diagnosis of primary human immunodeficiency virus infection: missed opportunities in acute care settings.

Authors:  Amy C Weintrob; Julieta Giner; Prema Menezes; Ericka Patrick; Daniel Kelly Benjamin; Jeffrey Lennox; Christopher D Pilcher; Joseph J Eron; Charles B Hicks
Journal:  Arch Intern Med       Date:  2003-09-22

6.  Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study.

Authors:  Sean Emery; Jacqueline A Neuhaus; Andrew N Phillips; Abdel Babiker; Calvin J Cohen; Jose M Gatell; Pierre-Marie Girard; Birgit Grund; Matthew Law; Marcelo H Losso; Adrian Palfreeman; Robin Wood
Journal:  J Infect Dis       Date:  2008-04-15       Impact factor: 5.226

7.  Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection.

Authors:  Martin Markowitz; Bach-Yen Nguyen; Eduardo Gotuzzo; Fernando Mendo; Winai Ratanasuwan; Colin Kovacs; Guillermo Prada; Javier O Morales-Ramirez; Clyde S Crumpacker; Robin D Isaacs; Havilland Campbell; Kim M Strohmaier; Hong Wan; Robert M Danovich; Hedy Teppler
Journal:  J Acquir Immune Defic Syndr       Date:  2009-11-01       Impact factor: 3.731

8.  Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.

Authors:  Anthony M Mills; Mark Nelson; Dushyantha Jayaweera; Kiat Ruxrungtham; Isabel Cassetti; Pierre-Marie Girard; Cassy Workman; Inge Dierynck; Vanitha Sekar; Carline Vanden Abeele; Ludo Lavreys
Journal:  AIDS       Date:  2009-08-24       Impact factor: 4.177

9.  Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the Italian atazanavir expanded access program and MASTER Cohorts.

Authors:  C Torti; G Lapadula; A Antinori; T Quirino; R Maserati; F Castelnuovo; F Maggiolo; A De Luca; G Paraninfo; F Antonucci; G Migliorino; A Lazzarin; G Di Perri; G Rizzardini; R Esposito; G Carosi
Journal:  Infection       Date:  2009-05-26       Impact factor: 3.553

10.  CD4+ count-guided interruption of antiretroviral treatment.

Authors:  W M El-Sadr; J D Lundgren; J D Neaton; F Gordin; D Abrams; R C Arduino; A Babiker; W Burman; N Clumeck; C J Cohen; D Cohn; D Cooper; J Darbyshire; S Emery; G Fätkenheuer; B Gazzard; B Grund; J Hoy; K Klingman; M Losso; N Markowitz; J Neuhaus; A Phillips; C Rappoport
Journal:  N Engl J Med       Date:  2006-11-30       Impact factor: 91.245

View more
  2 in total

Review 1.  Perinatally infected adolescents living with human immunodeficiency virus (perinatally human immunodeficiency virus).

Authors:  Maria Leticia S Cruz; Claudete A Cardoso
Journal:  World J Virol       Date:  2015-08-12

2.  Healthcare retention and clinical outcomes among adolescents living with HIV after transition from pediatric to adult care: a systematic review.

Authors:  Tiarney D Ritchwood; Vincenzo Malo; Cameron Jones; Isha W Metzger; Millicent Atujuna; Rebecca Marcus; Donaldson F Conserve; Lara Handler; Linda-Gail Bekker
Journal:  BMC Public Health       Date:  2020-08-03       Impact factor: 4.135

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.